Electronic Data Capture (EDC) using cellular technology: Implications for clinical trials and practice, and preliminary experience with the m-Womac ® Index in hip and knee OA patients

被引：11

作者：

Bellamy N. ^{[1
]}

Wilson C. ^{[1
]}

Hendrikz J. ^{[1
]}

Patel B. ^{[2
]}

Dennison S. ^{[2
]}

机构：

[1] Centre of National Research on Disability and Rehabilitation Medicine (CONROD), University of Queensland, Brisbane

[2] Exco InTouch, Harlow

来源：

Inflammopharmacology | 2009年 / 17卷 / 2期

关键词：

EDC; Health status measurement; Mobile phone; Osteoarthritis; WOMAC[!sup]®[!/sup;

D O I：

10.1007/s10787-008-8045-4

中图分类号：

学科分类号：

摘要：

Aim: The capture, analysis and utilisation of health status information are attended by logistic considerations and interpretation challenges. We report a preliminary evaluation of cellular technology in capturing WOMAC® NRS 3.1 Index data. Methods:: A Java midlet for delivering the WOMAC ® NRS3.1 Index on Nokia-6300, Motorola-V3 and Samsung-A711 mobile phones was developed by Exco InTouch. Following task orientation, patients completed the paper-based WOMAC® (p-WOMAC®) questionnaire, and then the three mobile phonebased WOMAC® (m-WOMAC®) applications, in random order. Results:: All 12 patients (age range = 55-82 years) successfully completed the m-WOMAC ® Index on each of the three phones, and all were found acceptable by patients. With respect to m-WOMAC® mean overall rank score, no significant difference was found between the 3 phones (Friedman's chi square (2 df) = 2.2, p = 0.34) however, Motorola V3 was favoured with the best mean rank. Pearson correlation between the average p-WOMAC® and average m-WOMAC® score was 0.996. Conclusions:: Patient reported ratings indicated the m-WOMAC® application performed well on all three phones. EDC provides unique opportunities for using quantitative measurement in both clinical practice and research. © 2009 Birkhäuser Verlag, Basel.

引用

页码：93 / 99

页数：6

共 54 条

[11]

Bellamy N., Buchanan W.W., Goldsmith C.H., Campbell J., Stitt L., Validation study of WOMAC: A health status instrument for measuring clinically important patient relevant outcomes following total hip or knee arthroplasty in osteoarthritis, J Orthop Rheumatol, 1, pp. 95-108, (1988)

[12]

Bellamy N., Kirwan J., Boers M., Brooks P., Strand V., Tugwell P., Altman R., Brandt K., Dougados M., Lequesne M., Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip and hand osteoarthritis. Consensus development in OMERACT III, J. Rheumatol, 24, pp. 799-802, (1997)

[13]

Bellamy N., Campbell J., Stevens J., Pilch L., Stewart C., Mahmood Z., Validation study of a computerized version of the Western Ontario and McMaster Universities VA3.0 Osteoarthritis Index, J Rheumatol, 24, pp. 2413-2415, (1997)

[14]

Bellamy N., Kaloni S., Pope J., Coulter K., Campbell J., Quantitative rheumatology: A survey of outcome measurement procedures in routine rheumatology outpatient practice in Canada, J Rheumatol, 25, pp. 852-858, (1998)

[15]

Bellamy N., Muirden K.D., Brooks P.M., Barraclough D., Tellus M.M., Campbell J., Quantitative rheumatology: A survey of outcome measurement procedures in routine rheumatology outpatient practice in Australia, J Rheumatol, 26, pp. 1593-1599, (1999)

[16]

Bellamy N., Campbell J., Syrotuik J., Comparative study of self-rating pain scales in osteoarthritis patients, Curr Med Res and Opinion, 15, 2, pp. 113-119, (1999)

[17]

Bellamy N., Krupa D., Markind J.E., Reicin A.S., Malmstrom K., WOMAC 20, 50, 70 response levels in patients treated with Rofecoxib for osteoarthritis, OA & Cart, 12, SUPPL. B, (2004)

[18]

Bellamy N., Krupa D., Markind J.E., Reicin A.S., Malmstrom K., Prevalence of patients with low intensity pain symptom severity states during treatment with rofecoxib and Ibuprofen for osteoarthritis, OA & Cart, 12, SUPPL. B, (2004)

[19]

Bellamy N., Bell M., Goldsmith C., Pericak D., Walker V., Raynauld J.-P., Torrance G., Tugwell P., Polisson R., Evaluation of WOMAC 20, 50, 70 Response Criteria in patients treated with hylan G-F 20 for knee osteoarthritis, Ann Rheum Dis, 64, pp. 881-885, (2005)

[20]

Bellamy N., Bell M.J., Goldsmith C.H., Pericak D., Walker V., Raynauld J.-P., Torrance G.W., Tugwell P., Polisson R., The effectiveness of hylan G-F 20 in patients with knee osteoarthritis: An application of two sets of response criteria developed by the OARSI and one set developed by OMERACT-OARSI, OA & Cart, 13, pp. 104-110, (2005)

← 1 2 3 4 5 6 →